There is a considerable amount of evidence suggesting that SHP2 loss can directly suppress the growth of tumor cells by restraining the RAS‐MAPK pathway or producing an antitumor immune microenvironment.[23, 24] Additionally, as a highly specific inhibitor of SHP2, the anti‐oncogenicity and anti‐inflammatory effects of SHP099 have also been intensively identified. Here, PTPN11 is linked to neoplasm.